Hyperoside attenuates diabetic nephropathy by activating the Nrf2/SLC7A11/GPX4 axis to restrain ferroptosis

Figure 7 Hyperoside mitigates oxidative stress and glomerular structural damage in diabetic nephropathy rats. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001, ^dP < 0.001. One-way analysis of variance + Tukey’s post hoc test; two-sided. Data are expressed as the mean ± SD; n = 6 rats per group. A: Renal malondialdehyde, Fe, superoxide dismutase, catalase, and glutathione; B: Representative hematoxylin and eosin, Masson, and periodic acid-Schiff staining with semi-quantitative scores calculated by two blinded observers; C: Western blot analysis of renal Nrf2, SLC7A11, and GPX4 expression. Fer-1: Ferrostatin-1; MDA: Malondialdehyde; SOD: Superoxide dismutase; CAT: Catalase; GSH: Glutathione; PAS: Periodic acid-Schiff; HE: Hematoxylin and eosin.